Kornimate/medical-research-clean huggingface dataset:
fluorescence endoscopy of esophageal carcinoma

Conditions: Esophageal Cancer

Summary: for locally advanced esophageal cancer (ec), neoadjuvant chemoradiotherapy (ncrt) for 5 weeks followed by esophagectomy and lymphadenectomy, if necessary, is standard of care. it is reported that the pathological complete response (pcr) rate after ncrt ranges from 16% to 43%, with a median of 26.5%. according to current clinical guidelines, patients who achieved pcr still go for surgery even though those patients who achieved pcr may not benefit from surgery. besides, about 50% of ec patients may have post-operative complications including pneumonia, anastomotic leakage, recurrent laryngeal nerve paralysis, which lead to low health-related quality of life (hqol). the golden standard to test the pathological response is by pathological assessment of the surgical specimen and thus after surgery. theoretically, if pcr after ncrt can be predicted accurately before surgery by advanced imaging techniques, patients could have a wait-and-see. the wait-and-see procedure includes regular follow-up and salvage surgery if recurrence is present. therefore, molecular fluorescence endoscopy (fme) using near-infrared fluorescence (nirf) tracer bevacizumab-800cw targeting vascular endothelial growth factor combined with high-definition white light (hd-wl) endoscopy is expected to be a promising technique to monitor pcr and fill the gap.

see brief summary

Eligibility criteria:
inclusion criteria: * locally advanced esophageal carcinoma (ct1b-4a n0-3 m0) in multi-disciplinary esophageal oncology meeting agreed on long course neoadjuvant chemoradiotherapy, followed by esophagectomy; * age ≥ 18 years; * written informed consent. exclusion criteria: * patients with psychological diseases or medical issues who are not able to sign informed consent form; * concurrent uncontrolled medical conditions; * pregnancy or breast feeding. a negative pregnancy test must be available for women of childbearing potential (i.e. premenopausal women with intact reproductive organs and women less than two years after menopause); * irradical endoscopic mucosal resection (emr) or endoscopic submucosal dissection (esd) of primary tumor prior to start of neoadjuvant chemoradiotherapy * received a different investigational drug within 30 days prior to the dose of bevacizumab-800cw; * history of infusion reactions to bevacizumab or other monoclonal antibodies;

Keywords: fluorescence endoscopy bevacizumab-800cw locally advanced esophageal cancer
the effectiveness of a nighttime positioning hand splint in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis.

Summary: the purpose of the present study was to evaluate the effectiveness of a nighttime positioning hand splint in patients with ra in terms of pain, grip and pinch strength, upper limb function, quality of life, and patient satisfaction. the hypothesis is that the stabilization of hand during nighttime could decrease pain and consequently improve quality of life.

the involvment of wrist and fingers is very common in ra and it could affect hand function and, consequently, affect activities of daily living (adl). some authors suggest that the rest of hand could decrease pain and inflammation. splints are external appliances that used in a specific body part provides the best alignment and rest in correct functional position. the goal of a hand, fingers and thumb in ra is stabilize the hand while the patients are not making theirs adl and try to decrease the pain.

Eligibility criteria:
inclusion criteria: * rheumatoid arthritis classified according to the acr criteria. * use of the same remissive drugs for at least 6 months before the intervention and the same doses of the same corticosteroids and nonsteroidal anti-inflammatory drugs for at least one month before the study. * a score ≥ 3 and ≤ 7 on a visual analog scale (vas) for pain in the more aching hand. * agreement to participate in the study, and signing of a free informed consent form. exclusion criteria: * presented deformities in the more aching hand that did not permit fabrication of the splint. * patients using any other type of upper limb splint. * patients with a surgery scheduled within 6 months after the study. * patients allergic to the splint material. * patients with mental deficiency. * patients who lived in inaccessible areas.

Keywords: rheumatoid arthritis hand splint occupational therapy
effects of extracorporeal shock wave therapy (eswt) and low intensity laser therapy (lllt) added to complete decongestive therapy (cdt) on extremity volume, pain intensity, functional status and quality of life in patients with postmastectomy stage 2 lymphedema

Conditions: Lymphedema, Breast Cancer

Summary: this study aimed to comparatively investigate the effects of eswt and lllt added to conventional cdt (which is the standard treatment for breast cancer-related lymphedema) on patients' limb volume, pain intensity, functional status and quality of life.

after being informed study and potential risks, all patient giving written informed consent will undergo screening period determine eligibility for study entry. the patients who meet the eligibility recruitments will get treatment into three groups in conventional complet decongestive therapy (cdt) program, electrocorporeal shock wave therapy (eswt) combined with cdt program and low level laser therapy (lllt) combined with cdt program

Eligibility criteria:
inclusion criteria: * female patients with unilateral lymphedema after breast cancer-related surgery patients whose chemotherapy and radiotherapy protocols have been completed patients with stage 2 lymphedema according to isl staging exclusion criteria: * patients with arm edema before breast cancer * patients with ongoing chemotherapy and radiotherapy those with metastatic breast cancer patients with acute infection patients with bmi \>35 patients with pregnancy patients who have previously received kdt patients with active cancer patients with recurrence or metastasis of breast cancer on follow-up imaging those with decompensated heart failure those with kidney failure patients with liver failure patients with a history of deep vein thrombosis in the last 3 months those who are allergic to the dressing materials to be applied patients with active infection or open wound on their extremities those with cognitive impairment patients with sensory deficits immobilized patients

Keywords: lymphedema eswt lllt
impact of a training in therapeutic education on the relation between care givers and their patients

Conditions: Cancer of Liver; Diabetes

Summary: this study aims to describe the impact of a training in therapeutic education on the relation between a caregiver and his/her patients. subjects are recruited among health professionals attending a training in therapeutic education. then they are asked to identify up to 5 of their patients to be contacted by the researcher for an interview. individual semi-structured interviews are conducted with 20 duo "caregivers / patients" before the training, 1 month and 6 months after the training.


Eligibility criteria:
inclusion criteria: * informed consent to participate to 3 interviews exclusion criteria: * not fluent french speaker * patient under guardianship
antibiotic exposure on gut microbiota and motility establishment in newborns

Conditions: NEC - Necrotizing Enterocolitis

Summary: this prospective cohort study aims to investigate the impact of early antibiotic exposure on the establishment of gut microbiota and motility in newborns, particularly preterm infants. the study will explore the correlation between antibiotic exposure, gut microbiota colonization, and 5-hydroxytryptamine (5-ht) levels, which are critical for gastrointestinal motility. the findings may provide insights into optimizing antibiotic use and improving gastrointestinal health in neonates.


Eligibility criteria:
inclusion criteria: * newborns admitted within 72 hours of birth * gestational age 24-36 weeks (preterm) and term infants * informed consent obtained from parents or guardian exclusion criteria: * congenital gastrointestinal malformations (e.g., intestinal atresia, hirschsprung's disease) * severe systemic or organ-specific diseases * expected mortality due to severe illness
triad project: qualitative study of adolescent depression and smoking

Conditions: Adolescent - Emotional Problem; Smoking

Summary: it has been shown in the adult literature that smoking is related to depression and visa versa. not much is known about how this relationship is started or if one perhaps leads to the other. we are performing 1 hour long interviews with adolescents ages 12-19 who meet criteria for major depression and who smoke. they are interviewed along with their parent. questions center around their view of depression and their history of depression as well as questions around their smoking as well as the interrelationships between the two. transcripts are made of the interview and are being analyzed for themes.


Eligibility criteria:
inclusion criteria: * 12-19 years old * major depression * smoke cigarettes * lives with parents * no confidentiality issues related to smoking exclusion criteria: * non english speaking * suicidal ideation * pregnant

Keywords: adolescent depression adolescent smoking
study of the safety and immune response of an investigational mrna vaccine for the prevention of respiratory syncytial virus and/or human metapneumovirus in participants aged 18 to 49 years and 60 years and older

Conditions: Respiratory Syncytial Virus Infection; Healthy Volunteers; Metapneumovirus Infection

Summary: the purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mrn)a vaccine for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus (rsv) and/or human metapneumovirus (hmpv) in older adults. a single intramuscular (im) injection of 3 to 4 different doses of the rsv/hmpv mrna vaccine candidate formulated with 2 different lipid nanoparticles (lnp) will be administered to healthy participants aged 18 to 49 years and 60 years and older. treatment: * rsv/hmpv mrna / lnp 1 at 3-4 different doses or, * rsv/hmpv mrna / lnp 2 at 3-4 difference doses or, * rsv mrna / lnp 1 at 1 dose or, * hmpv mrna / lnp 1 at 1 dose

study duration per participant is approximately 6 months.

Eligibility criteria:
inclusion criteria: -informed consent form (icf) has been signed and dated exclusion criteria: participants are excluded from the study if any of the following criteria apply: -any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives. --the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
scm muscle released in patients with cervicogenic headache

Conditions: Cervicogenic Headache

Summary: sternocleidomastoid syndrome is often characterized by referred pain in other areas. like all muscles, the scm can develop tight, and non-contracting bands called trigger points that can refer pain elsewhere. for the scm, the trigger point referral areas are the eye and forehead, the back of the head (occiput), front of the neck, cheek, and side of the head. trigger points can be treated by direct manual massage, dry needling, or platelet-poor plasma injection.

cervicogenic headache is a specific type of headache that originates from the cervical spine and is typically chronic in nature. diagnostic criteria for cgh have been established by the international headache society (ihs) and are cited extensively in the literature. diagnosis of cgh through manual examination is a more recent practice. to our knowledge, no systematic review of manual diagnosis of cgh has been performed.

Eligibility criteria:
inclusion criteria: * history of cgh ≥ 3 months at baseline 1, ≥5 days of cgh per month * cgh intensity ≥3 (0-10 scale) * cervical spine dysfunction (cervical joint tenderness and/or restricted segmental motion) * clear temporal sequence linking the source of cgh to the neck: headache preceded by neck pain, stiffness, movement and/or awkward postures exclusion criteria: * other headaches within one year of enrollment (e.g. migraine occurring on \>1 day per month in the last year, medication overuse, daily, cluster, temporomandibular joint dysfunction related headaches, sinus, posttraumatic, tumor and glaucoma related, occipital neuralgia, metabolic/toxic/substance abuse related). * spinal manipulative therapy, massage or exercise therapy for neck pain or headaches in the previous 3 months. any other types of care by a licensed provider in the previous month for headaches or neck pain * contraindications to study treatments (e.g., inflammatory arthropathies, cervical instability, severe osteoporosis, vertigo, dizziness) * daily prescription or nonprescription pain medication; corticosteroid use in previous month * cancer in the past five years * ear problem

Keywords: trigger points sternocleidomastoid headaches
surgery for adhesive small bowel obstruction in a defined population: a cohort study

Conditions: Adhesive Small Bowel Obstruction

Summary: a cohort study of patients operated for adhesive small bowel obstruction (sbo) during a five-year period

it is a population-based cohort study of patients operated for adhesive small bowel obstruction during a five-year period (2007-2012) in two swedish neighboring regions. patients were identified by a broad search of operation and icd codes. preoperative data as age, gender, co-morbidity, previous surgery was registered as well as mechanisms of obstruction and intraoperative data. short and long-term complications were analyzed. patients were followed to 31st january 2017 , last medical note or death.

Eligibility criteria:
inclusion criteria: * \> 18 years old * surgery for adhesive small bowel obstructions during the time period 2007-2011 in uppsala county and gävle county, sweden exclusion criteria: none

Keywords: cohort surgery adhesive small bowel obstruction
comparison of the accuracy of different intraocular lens power calculation formulas in cataract patients with prior radial keratotomy

Conditions: Cataract

Summary: the web-based barret true k formula with no history formula has been proven to be a good choice for cataract patients after rk in several studies. the american society of cataract and refractive surgeons provides several iol formulas for cataract patients who have undergone previous corneal refractive surgery. in cases where only iol-master data are available, holladay 1 (double-k) \[holladay 1 (d-k)\] can be used for iol power calculation in cataract patients with a history of rk. the traditional haigis formula has also been shown to be effective for cataract patients after rk. to compare the accuracy of four intraocular lens (iol) power calculation formulas in cataract patients after rk. they are barrett true-k formula, holladay 1(d-k) formula, haigis formula, and mm formula.

myopia is the most common cause of distance vision impairment. the prevalence of myopia has increased dramatically in the past few decades, especially in china. corneal refractive surgery is an effective method to correct adult myopia. radial keratotomy (rk) is one of the corneal refractive surgeries developed in the 1980s. thirty years ago, many myopic patients underwent rk. as patients age, more and more patients have cataracts requiring cataract extraction and intraocular lens (iol) implantation. the selection of appropriate and accurate iol is an important factor to improve patient satisfaction. recent studies have compared the accuracy of the newly developed iol formula in patients with previous rk cataract. however, as a country with myopia and myopia surgery, there is no similar study in china. in addition, most patients with cataract after rk had lost ocular data before rk surgery. for rk patients without previous ocular data, how to accurately calculate the iol power is still a clinical challenge.

Eligibility criteria:
inclusion criteria: * had a previous history of rk surgery * iol-master is available * there were no intraoperative and postoperative complications * obvious refraction was performed 1 to 6 months after cataract surgery exclusion criteria: * the investigator decided that it was not suitable for this study

Keywords: cataract rk surgery formula
study of the effectiveness of dydrogesterone in the treatment of endometriosis-related pain

Conditions: Endometriosis

Summary: the study is an observational, multicenter, prospective, single arm study to evaluate the efficacy of dydrogesterone in endometriosis-related pain (eap).


Eligibility criteria:
inclusion criteria: * female, ≥18 and ≤45 years of age. * with normal menstrual cycles (according to the international federation of gynecology and obstetrics \[figo\]-2018 classification system) in the preceding 6 months before cycle 0, defined as menstrual frequency ≥24 to ≤38 days, menstrual duration ≤8 days, shortest to longest cycle variation ≤7-9 days, normal flow volume (patient determined) and no intermenstrual bleeding. * have clinically or surgically diagnosed endometriosis according to routine clinical practice. * complaints of erp. * prescribed treatment with duphaston® according to the local approved label for treatment of endometriosis 10 mg bid or tid from the 5th to the 25th day of the menstrual period. * signed informed consent form (icf). exclusion criteria: * with definite diagnosis of adenomyosis confirmed by clinical diagnosis or histopathology. * routine consumption of analgesics other than for the pain of endometriosis. * patients receiving hormonal treatment (e.g., dienogest, levonorgestrel releasing intrauterine system, dydrogesterone, etc.) or hormonal contraceptives (including intrauterine devices, contraceptive patches, contraceptive rings, oral contraceptives, etc.) during the previous menstrual cycle prior to cycle 0. * ongoing pregnancy. * menopause or premature ovarian failure. * had surgery within 3 months before enrollment or have planned surgery during the study. * any coexisting disease(s) with or without chronic concomitant medication that may affect the assessment of pain intensity at the investigator's judgment. * with any metabolic and genetic diseases that may affect pregnancy and fetus at the investigator's judgment. * with contraindications for dydrogesterone treatment listed in the locally approved label (instructions for the medical use of duphaston®). * other conditions that made the patient's participation impossible (based on the investigator's decision). * fertility treatments requiring assisted reproductive technology. * patients simultaneous participating in any interventional clinical study during observation period.
immediate radiotherapy or observation after surgery for melanoma involving lymph nodes

Conditions: Malignant Melanoma; Lymph Node Disease

Summary: this trial seeks to establish the role of post-operative radiotherapy in patients who have had surgery for melanoma involving lymph nodes and who are at high risk of recurrence.

this is a randomised phase iii trial which is being performed on patients at high risk of local recurrence after having a lymphadenectomy for stage 3 melanoma. the control arm is surgery alone with radiotherapy reserved for those who recur. the study arm is surgery plus post-operative radiotherapy. all 3 major node sites are eligible. the radiation dose administered is 48gy in 20 fractions. it is likely to be the only study of its kind ever performed. the target is 230 patients.

Eligibility criteria:
inclusion criteria: * regional macroscopic nodal metastatic melanoma in one nodal basin region only which has been completely resected. * melanoma involving lymph nodes at high risk of local recurrence (details in protocol) * no evidence of metastases * no active major cancer within 5 years * normal blood tests * who performance status of 0 or 1 * radiotherapy must be able to be commenced within 12 weeks of lymphadenectomy * patient must not be pregnant and if fertile must use a medically acceptable contraceptive throughout treatment * no major concurrent illnesses likely to cause death within 2 years * written informed consent has been given exclusion criteria: * evidence of active or previous local recurrence or in transit disease * evidence of distant metastases on clinical or radiological investigation * patients with prior cancers

Keywords: melanoma lymph node disease adjuvant radiotherapy lymphoedema
study comparing bioavailability of oral formulations of vabicaserin

Conditions: Schizophrenia

Summary: the purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin.


Eligibility criteria:
inclusion criteria: * healthy men aged 18-50 years. exclusion criteria: * any significant disease state. * history of drug or alcohol abuse within 1 year. * abnormal liver function tests.
heal-laa clinical trial

Conditions: Atrial Fibrillation; Bleeding; Stroke

Summary: the primary objective of this study is to collect real-world data on watchman flx™ pro left atrial appendage closure (laac) device in patients with non-valvular atrial fibrillation.


Eligibility criteria:
inclusion criteria: * subject is of legal age to participate in the study. * subject has documented non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve). * subject is clinically indicated for and is treated or attempted to be treated with a watchman flx™ pro device. * subject or legal representative is able to understand and willing to provide written informed consent to participate in the study. * subject is able and willing to return for required follow-up visits and examinations. exclusion criteria: * subject has a documented life expectancy of less than 6 months. * subject is currently enrolled in another investigational study, except if the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatment. * intracardiac thrombus is present. * an atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present. * the laa anatomy will not accommodate a closure device. * the patient has known hypersensitivity to any portion of the device material or the individual components such that the use of the watchman flx™ pro device is contraindicated. * any of the customary contraindications for other percutaneous catheterization procedure (e.g., patient size too small to accommodate transesophageal echocardiography (tee) probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present. * there are contraindications to the use of anticoagulation therapy, aspirin, or p2y12 inhibitor. * subject is of childbearing potential and is, or plans to become, pregnant during the time of the study (method of assessment per study physician's discretion).